Amarin Corp

Voir l'organigramme avec ses 21 principaux dirigeants

Biographies les plus recherchées chez Amarin Corp

• Karim Mikhail, President and Chief Executive Officer
• Joseph Zakrzewski, Director
• David Stack, Director

Changements de dirigeants chez Amarin Corp

• Erin Enright, a rejoint l'entreprise comme Director  (publié le 19 mai 2022).
• Alfonso Zulueta, a rejoint l'entreprise comme Director  (publié le 19 mai 2022).

Créer une alerte
pour suivre les mouvements de dirigeants chez Amarin Corp.

Amarin Corp a 1 999 concurrents dont Pfizer (Etats—Unis), Johnson & Johnson (Etats—Unis) et Roche (Suisse).

Actualités en fusion/acquisition en Pharmacie.

• Zentalis Pharmaceuticals vient d'annoncer une levée de fonds de 200 millions de dollars. (publié le 19 mai 2022).
• Pfizer has announced the acquisition of Biohaven Pharmaceutical  (publié le 12 mai 2022).
• Corden Pharma and Astorg Partners have announced they will merge  (publié le 4 mai 2022)..

Contacts en Pharmacie

• Albert Bourla - Chief Executive Officer and Chairman of the Board chez Pfizer
• Joaquin Duato - Chief Executive Officer and Director chez Johnson & Johnson
• Luisa Bartorelli - Chief Patent Counsel chez Cosmo Pharmaceuticals

En savoir plus sur le secteur Pharmacie >

Derniers communiqués de presse par Amarin Corp

• Amarin Announces Appointment of New Directors and Board Leadership Changes | Amarin Corporation plc
• Research Presented at the American Heart Association’s Quality of Care and Outcomes Research (QCOR) Scientific Sessions Indicate Potential for VASCEPA® (icosapent ethyl) to Reduce Major Adverse Cardiovascular (CV) Events and Associated Costs | Amarin Corp
• Amarin to Present at Two Upcoming Investor Conferences | Amarin Corporation plc
• Amarin Reports First Quarter 2022 Financial Results and Provides Business Update | Amarin Corporation plc
• New Analysis Reveals Icosapent Ethyl Significantly Reduces Risk of Major Cardiovascular Events in Patients with Prior Myocardial Infarction (Heart Attack) | Amarin Corporation plc
• Amarin Partner HLS Therapeutics Completes Reimbursement Negotiations with Pan-Canadian Pharmaceutical Alliance (pCPA) for VASCEPA® (icosapent ethyl) | Amarin Corporation plc
• Amarin to Report Third Quarter 2020 Results and Host Conference Call on November 5, 2020 | Amarin Corporation plc
• VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Percutaneous Coronary Intervention (PCI) in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at Transcatheter Cardiovascular Therapeutics (TCT
• Latest Research Evaluating VASCEPA® (Icosapent Ethyl) Mechanisms of Action Presented at European Atherosclerosis Society (EAS) Congress 2020 | Amarin Corporation plc
• Amarin to Present at the 2020 Cantor Virtual Global Healthcare Conference | Amarin Corporation plc
• Voir plus de communiqués de presse Close

Réseaux sociaux à propos de Amarin Corp

• Amarin Corp sur Wikipédia, Google News & Yahoo Finance en 1-click
• Amarin Corp sur LinkedIn, Twitter & YouTube en 1-click

Contacter par email ses dirigeants dont Karim Mikhail

Appelez Amarin Corp au +353 ...

Voir l'organigramme

Register to receive your alert

Signaler une erreur